NRAS and melanoma: Unlike many other tumor types, new cases and mortality of melanoma are still rising.11,12 While some oncogenic driver mutations, such as BRAF and NRAS, have been identified in melanoma, the efficacy of therapies is limited and the prognosis of metastatic melanoma patients remains poor.13 Many spontaneous, oncogene-driven zebrafish models of melanoma exist.